Program
Cannabidiol
Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.
Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.
Drug pageCannabidiol: every studyMany companies study it; this page follows only the 64 they lead. All 316 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 315 open or running | phase 4since Oct 17, 2019 | Oct 7, 2010 | Aug 1, 2027phase 4 · NCT05044819 |
| INSYS Therapeuticsits history only | 50 open or running | phase 3since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Radius Pharmaceuticalsits history only | 50 open or running | phase 3since Jan 26, 2018 | Jul 22, 2016 | none ahead |
| Cardiol Therapeuticsits history only | 41 open or running | phase 3since Nov 2, 2020 | Nov 2, 2020 | none ahead |
| Pure Greenits history only | 40 open or running | phase 2since Sep 10, 2019 | Sep 10, 2019 | none ahead |
| Canopy Growthits history only | 30 open or running | phase 2since Aug 29, 2019 | Aug 29, 2019 | none ahead |
| Botanix Pharmaceuticalsits history only | 20 open or running | phase 2since Jun 19, 2018 | Jun 19, 2018 | none ahead |
| Stero Biotechsits history only | 20 open or running | phase 2since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Avecho Biotechnologyits history only | 11 open or running | phase 3since Apr 23, 2023 | Apr 23, 2023 | Sep 30, 2027phase 3 · NCT05840822 |
| Bod Australiaits history only | 10 open or running | phase 2since Dec 20, 2021 | Dec 20, 2021 | none ahead |
| dsm-firmenichits history only | 10 open or running | phase 1since Aug 20, 2024 | Aug 20, 2024 | none ahead |
| EmpowerPharmits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
| Kalytera Therapeutics Israelits history only | 10 open or running | phase 2since Feb 10, 2019 | Feb 10, 2019 | none ahead |
| Laboratorio Elea Phoenixits history only | 11 open or running | phase 2since Sep 30, 2024 | Sep 30, 2024 | none ahead |
| Pure Green Pharmaceuticalsits history only | 10 open or running | phase 2since Mar 2, 2023 | Mar 2, 2023 | none ahead |
| Tiamat Australia Ptyits history only | 10 open or running | phase 1since Feb 14, 2025 | Feb 14, 2025 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Research UK and Benuvia Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jazz Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Oct 7, 2010.
- Nov 16, 20152 phase 2 studies in EpilepsyNCT02607904, NCT02607891
- Jun 9, 2016Named cannabidiolINNProposed as its International Nonproprietary Name in WHO's List 115 · before, GWP42003-P, GWP42003
- Nov 1, 20162 phase 3 studies in Spasms, InfantileNCT02953548, NCT02954887
- Feb 19, 2019Phase 3 study in Rett SyndromeNCT03848832 · 29 enrolled · United States, Italy, Spain and more
- Oct 17, 2019Phase 4 study in Lennox Gastaut SyndromeNCT04133480
- Jan 30, 2020Phase 3 study in Rett SyndromeNCT04252586 · 21 enrolled · United States, Australia, Canada and more
- May 27, 2020Phase 2 study in SchizophreniaNCT04421456 · 95 enrolled · United States, Poland, Serbia and more
- Jul 21, 2020Phase 3 study in EpilepsyNCT04485104 · 3 enrolled · United States, Italy, Spain
- Feb 4, 2021Phase 2 study in Autism Spectrum DisorderNCT04745026 · 103 enrolled · United States, Australia, Canada and more
- Aug 30, 2021Phase 4 study in Lennox Gastaut SyndromeNCT05044819 · 154 enrolled · United States
- Mar 11, 2022Phase 3 study in EpilepsyNCT05288283 · 3 enrolled · United States, Italy
- May 9, 2023Phase 4 study in SeizuresNCT05864846 · 79 enrolled · United States, Canada, Poland and more
- Nov 14, 2025Phase 1 study in SeizuresNCT07233239 · 100 planned · United States
- Jul 20, 20262 phase 3 studiesNCT07723976, NCT07723963
- Jul 22, 2026Phase 4 study in Lennox Gastaut SyndromeNCT07728097 · 40 planned · United States
Ahead
- Aug 1, 2027Primary completion: phase 4 study in Lennox Gastaut SyndromeNCT05044819
- Nov 29, 2027Primary completion: phase 1 study in SeizuresNCT07233239
- Aug 1, 2028Primary completion: phase 3 study in Myoclonic Epilepsy, JuvenileNCT07723963
- Dec 28, 2028Primary completion: phase 4 study in Lennox Gastaut SyndromeNCT07728097
TargetBeta
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rimonabantrule | Sanofi | phase 3 | 39 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 31 Jazz Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07728097Lennox Gastaut Syndrome · United States | 4 | Not yet recruiting | Dec 28, 2028 | 40 |
| NCT07723976Developmental and Epileptic Encephalopathy (DEE) · United States, Australia, Hungary and more | 3 | Recruiting | Sep 4, 2029 | 120 |
| NCT07723963Myoclonic Epilepsy, Juvenile · United States | 3 | Recruiting | Aug 1, 2028 | 260 |
| NCT07233239Seizures · United States | 1 | Recruiting | Nov 29, 2027 | 100 |
| NCT05864846Seizures · United States, Canada, Poland and more | 4 | Completed | Apr 6, 2026 | 79 |
| NCT05288283Epilepsy · United States, Italy | 3 | Terminated | Sep 28, 2023 | 3 |
| NCT05044819Lennox Gastaut Syndrome · United States | 4 | Active, not recruiting | Aug 1, 2027 | 154 |
| NCT04745026Autism Spectrum Disorder · United States, Australia, Canada and more | 2 | Completed | Dec 21, 2023 | 103 |
| NCT04485104Epilepsy · United States, Italy, Spain | 3 | Terminated | Jan 28, 2025 | 3 |
| NCT04421456Schizophrenia · United States, Poland, Serbia and more | 2 | Terminated | Mar 16, 2022 | 95 |
| NCT04252586Rett Syndrome · United States, Australia, Canada and more | 3 | Terminated | Jun 9, 2021 | 21 |
| NCT04133480Lennox Gastaut Syndrome | 4 | Withdrawn | Dec 2021 | 0 |
| NCT03848832Rett Syndrome · United States, Italy, Spain and more | 3 | Terminated | Jan 21, 2021 | 29 |
| NCT02954887Spasms, Infantile · United States, Poland | 3 | Completed | Jun 13, 2019 | 9 |
| NCT02953548Spasms, Infantile · United States, Poland | 3 | Completed | May 7, 2018 | 9 |
| NCT02607904Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | May 27, 2019 | 30 |
| NCT02607891Epilepsy · Netherlands, Spain, Sweden | 2 | Completed | Sep 11, 2018 | 35 |
| NCT02565108Epilepsy · Spain, United Kingdom | 2 | Completed | Jul 21, 2016 | 20 |
| NCT02564952Epilepsy · Spain, United Kingdom | 2 | Completed | Jun 7, 2017 | 18 |
| NCT02544763Tuberous Sclerosis · United States, Australia, Netherlands and more | 3 | Completed | Jan 22, 2019 | 224 |
| NCT02544750Tuberous Sclerosis · United States | 3 | Completed | Jun 11, 2021 | 199 |
| NCT02224703Epilepsy · United States, Australia, Israel and more | 3 | Completed | Apr 9, 2018 | 199 |
| NCT02224690Epilepsy · United States, Netherlands, Poland | 3 | Completed | Mar 18, 2016 | 171 |
| NCT02224573Epilepsy | 3 | Completed | Sep 24, 2020 | 681 |
| NCT02224560Epilepsy · United States, France, Spain and more | 3 | Completed | May 19, 2016 | 225 |
| NCT02091375Epilepsy · United States, France, Poland and more | 3 | Completed | Nov 26, 2015 | 120 |
| NCT02091206Epilepsy · United States, United Kingdom | 2 | Completed | Mar 9, 2015 | 34 |
| NCT02006628Schizophrenia · Poland, Romania, United Kingdom | 2 | Completed | Jan 8, 2015 | 88 |
| NCT01562314Colitis, Ulcerative · United Kingdom | 2 | Completed | Aug 5, 2014 | 60 |
| NCT01284634Fatty Liver · United Kingdom | 2 | Completed | Jul 13, 2012 | 25 |
| NCT01217112Dyslipidemias · United Kingdom | 2 | Completed | May 2012 | 62 |
How it is read
Names in the registry
- “GWP42003-P”, 17 entries
- “Cannabidiol Oral Solution”, 10 entries
- “Cannabidiol”, 7 entries
- “CBD”, 5 entries
- “GWP42003”, 4 entries
Codes read as this program: JZP926.
Conditions, from the studies’ own filings
- Epilepsy, 7 studies
- Lennox Gastaut Syndrome, 6 studies
- Epilepsies, Myoclonic, 5 studies
- Seizures, 4 studies
- Spasms, Infantile, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.